Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter

N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Neural Transmission 2009-12, Vol.116 (12), p.1591-1599
Hauptverfasser: Cozzi, Nicholas V., Gopalakrishnan, Anupama, Anderson, Lyndsey L., Feih, Joel T., Shulgin, Alexander T., Daley, Paul F., Ruoho, Arnold E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1599
container_issue 12
container_start_page 1591
container_title Journal of Neural Transmission
container_volume 116
creator Cozzi, Nicholas V.
Gopalakrishnan, Anupama
Anderson, Lyndsey L.
Feih, Joel T.
Shulgin, Alexander T.
Daley, Paul F.
Ruoho, Arnold E.
description N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT, N -methyl- N -isopropyltryptamine (MIPT), N,N -dipropyltryptamine (DPT), and N,N -diisopropyltryptamine. We then tested the abilities of these N,N -dialkyltryptamines to inhibit [ 3 H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [ 3 H]paroxetine binding to the SERT and [ 3 H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [ 3 H]5-HT transport at the SERT with K I values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [ 3 H]5-HT transport with K I values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [ 3 H]paroxetine binding to SERT and of [ 3 H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.
doi_str_mv 10.1007/s00702-009-0308-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21267762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733589521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhYMoTjv6AG4kuNBVaVKpys9SZvyDATe6Dknq1lTGqqRNUoP9Lj6saaqhRdDNDdx85xwuB6HnlLyhhIi3uQ7SNoSohjAiG_kA7WjH-oZ2nD1Eu7okjep5d4Ge5HxHCKFUyMfogirRc8bpDv269guU6TCXdNgXs_gA2IQBxzJBwpOZ59X5EG8heIfPTMbwc_LWF5xXm0syBbCFydz7mLApuKpxhhRLDD7gtaq-Q5WbkPcxlep8zDhC95C9mwEvMcQt_Q_qKXo0mjnDs9N7ib59eP_16lNz8-Xj56t3N43rOlUa6KDtpRFkUNJ14KQV0oA1ijErWkMGaodxpG4Ug5HjIFzPpbKjkYxaZYVil-j15rtP8ccKuejFZwfzbALENWvBWC9V39JKvvov2dKWC8HbCr78C7yLawr1isoIyQnlokJ0g1yKOScY9T75xaSDpkQfG9Zbw7o2rI8Na1k1L07Gq11gOCtOlVag3YBcv8ItpHPyv11_AyO5tvI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217860167</pqid></control><display><type>article</type><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><source>MEDLINE</source><source>Springer LINK 全文期刊数据库</source><creator>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</creator><creatorcontrib>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</creatorcontrib><description>N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT, N -methyl- N -isopropyltryptamine (MIPT), N,N -dipropyltryptamine (DPT), and N,N -diisopropyltryptamine. We then tested the abilities of these N,N -dialkyltryptamines to inhibit [ 3 H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [ 3 H]paroxetine binding to the SERT and [ 3 H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [ 3 H]5-HT transport at the SERT with K I values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [ 3 H]5-HT transport with K I values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [ 3 H]paroxetine binding to SERT and of [ 3 H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/s00702-009-0308-8</identifier><identifier>PMID: 19756361</identifier><identifier>CODEN: JNTRF3</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Animals ; Basic Neurosciences ; Blood Platelets - chemistry ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; Cell Line ; Genetics and Immunology - Original Article ; Hallucinogens - chemistry ; Hallucinogens - metabolism ; Hallucinogens - pharmacology ; Humans ; Medicine ; Medicine &amp; Public Health ; N,N-Dimethyltryptamine - chemistry ; N,N-Dimethyltryptamine - metabolism ; N,N-Dimethyltryptamine - pharmacology ; Neurology ; Neurosciences ; Paroxetine - chemistry ; Paroxetine - metabolism ; Paroxetine - pharmacology ; Psychiatry ; Rats ; Serotonin - chemistry ; Serotonin - metabolism ; Serotonin Plasma Membrane Transport Proteins - chemistry ; Serotonin Plasma Membrane Transport Proteins - metabolism ; Serotonin Uptake Inhibitors - chemistry ; Serotonin Uptake Inhibitors - metabolism ; Serotonin Uptake Inhibitors - pharmacology ; Spodoptera ; Tetrabenazine - analogs &amp; derivatives ; Tetrabenazine - chemistry ; Tetrabenazine - metabolism ; Tetrabenazine - pharmacology ; Tritium ; Tryptamines - chemistry ; Tryptamines - metabolism ; Tryptamines - pharmacology ; Vesicular Monoamine Transport Proteins - chemistry ; Vesicular Monoamine Transport Proteins - metabolism</subject><ispartof>Journal of Neural Transmission, 2009-12, Vol.116 (12), p.1591-1599</ispartof><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</citedby><cites>FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00702-009-0308-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00702-009-0308-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19756361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Gopalakrishnan, Anupama</creatorcontrib><creatorcontrib>Anderson, Lyndsey L.</creatorcontrib><creatorcontrib>Feih, Joel T.</creatorcontrib><creatorcontrib>Shulgin, Alexander T.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><creatorcontrib>Ruoho, Arnold E.</creatorcontrib><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm</addtitle><addtitle>J Neural Transm (Vienna)</addtitle><description>N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT, N -methyl- N -isopropyltryptamine (MIPT), N,N -dipropyltryptamine (DPT), and N,N -diisopropyltryptamine. We then tested the abilities of these N,N -dialkyltryptamines to inhibit [ 3 H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [ 3 H]paroxetine binding to the SERT and [ 3 H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [ 3 H]5-HT transport at the SERT with K I values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [ 3 H]5-HT transport with K I values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [ 3 H]paroxetine binding to SERT and of [ 3 H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</description><subject>Animals</subject><subject>Basic Neurosciences</subject><subject>Blood Platelets - chemistry</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>Cell Line</subject><subject>Genetics and Immunology - Original Article</subject><subject>Hallucinogens - chemistry</subject><subject>Hallucinogens - metabolism</subject><subject>Hallucinogens - pharmacology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>N,N-Dimethyltryptamine - chemistry</subject><subject>N,N-Dimethyltryptamine - metabolism</subject><subject>N,N-Dimethyltryptamine - pharmacology</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Paroxetine - chemistry</subject><subject>Paroxetine - metabolism</subject><subject>Paroxetine - pharmacology</subject><subject>Psychiatry</subject><subject>Rats</subject><subject>Serotonin - chemistry</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Plasma Membrane Transport Proteins - chemistry</subject><subject>Serotonin Plasma Membrane Transport Proteins - metabolism</subject><subject>Serotonin Uptake Inhibitors - chemistry</subject><subject>Serotonin Uptake Inhibitors - metabolism</subject><subject>Serotonin Uptake Inhibitors - pharmacology</subject><subject>Spodoptera</subject><subject>Tetrabenazine - analogs &amp; derivatives</subject><subject>Tetrabenazine - chemistry</subject><subject>Tetrabenazine - metabolism</subject><subject>Tetrabenazine - pharmacology</subject><subject>Tritium</subject><subject>Tryptamines - chemistry</subject><subject>Tryptamines - metabolism</subject><subject>Tryptamines - pharmacology</subject><subject>Vesicular Monoamine Transport Proteins - chemistry</subject><subject>Vesicular Monoamine Transport Proteins - metabolism</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEUhYMoTjv6AG4kuNBVaVKpys9SZvyDATe6Dknq1lTGqqRNUoP9Lj6saaqhRdDNDdx85xwuB6HnlLyhhIi3uQ7SNoSohjAiG_kA7WjH-oZ2nD1Eu7okjep5d4Ge5HxHCKFUyMfogirRc8bpDv269guU6TCXdNgXs_gA2IQBxzJBwpOZ59X5EG8heIfPTMbwc_LWF5xXm0syBbCFydz7mLApuKpxhhRLDD7gtaq-Q5WbkPcxlep8zDhC95C9mwEvMcQt_Q_qKXo0mjnDs9N7ib59eP_16lNz8-Xj56t3N43rOlUa6KDtpRFkUNJ14KQV0oA1ijErWkMGaodxpG4Ug5HjIFzPpbKjkYxaZYVil-j15rtP8ccKuejFZwfzbALENWvBWC9V39JKvvov2dKWC8HbCr78C7yLawr1isoIyQnlokJ0g1yKOScY9T75xaSDpkQfG9Zbw7o2rI8Na1k1L07Gq11gOCtOlVag3YBcv8ItpHPyv11_AyO5tvI</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Cozzi, Nicholas V.</creator><creator>Gopalakrishnan, Anupama</creator><creator>Anderson, Lyndsey L.</creator><creator>Feih, Joel T.</creator><creator>Shulgin, Alexander T.</creator><creator>Daley, Paul F.</creator><creator>Ruoho, Arnold E.</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</title><author>Cozzi, Nicholas V. ; Gopalakrishnan, Anupama ; Anderson, Lyndsey L. ; Feih, Joel T. ; Shulgin, Alexander T. ; Daley, Paul F. ; Ruoho, Arnold E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-e4e258a70d98c4ec8b78aeba933b72a0d1bdff1cf7da8fd7c5689bfa831b9b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Basic Neurosciences</topic><topic>Blood Platelets - chemistry</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>Cell Line</topic><topic>Genetics and Immunology - Original Article</topic><topic>Hallucinogens - chemistry</topic><topic>Hallucinogens - metabolism</topic><topic>Hallucinogens - pharmacology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>N,N-Dimethyltryptamine - chemistry</topic><topic>N,N-Dimethyltryptamine - metabolism</topic><topic>N,N-Dimethyltryptamine - pharmacology</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Paroxetine - chemistry</topic><topic>Paroxetine - metabolism</topic><topic>Paroxetine - pharmacology</topic><topic>Psychiatry</topic><topic>Rats</topic><topic>Serotonin - chemistry</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Plasma Membrane Transport Proteins - chemistry</topic><topic>Serotonin Plasma Membrane Transport Proteins - metabolism</topic><topic>Serotonin Uptake Inhibitors - chemistry</topic><topic>Serotonin Uptake Inhibitors - metabolism</topic><topic>Serotonin Uptake Inhibitors - pharmacology</topic><topic>Spodoptera</topic><topic>Tetrabenazine - analogs &amp; derivatives</topic><topic>Tetrabenazine - chemistry</topic><topic>Tetrabenazine - metabolism</topic><topic>Tetrabenazine - pharmacology</topic><topic>Tritium</topic><topic>Tryptamines - chemistry</topic><topic>Tryptamines - metabolism</topic><topic>Tryptamines - pharmacology</topic><topic>Vesicular Monoamine Transport Proteins - chemistry</topic><topic>Vesicular Monoamine Transport Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cozzi, Nicholas V.</creatorcontrib><creatorcontrib>Gopalakrishnan, Anupama</creatorcontrib><creatorcontrib>Anderson, Lyndsey L.</creatorcontrib><creatorcontrib>Feih, Joel T.</creatorcontrib><creatorcontrib>Shulgin, Alexander T.</creatorcontrib><creatorcontrib>Daley, Paul F.</creatorcontrib><creatorcontrib>Ruoho, Arnold E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cozzi, Nicholas V.</au><au>Gopalakrishnan, Anupama</au><au>Anderson, Lyndsey L.</au><au>Feih, Joel T.</au><au>Shulgin, Alexander T.</au><au>Daley, Paul F.</au><au>Ruoho, Arnold E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter</atitle><jtitle>Journal of Neural Transmission</jtitle><stitle>J Neural Transm</stitle><addtitle>J Neural Transm (Vienna)</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>116</volume><issue>12</issue><spage>1591</spage><epage>1599</epage><pages>1591-1599</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTRF3</coden><abstract>N,N -dimethyltryptamine (DMT) is a potent plant hallucinogen that has also been found in human tissues. When ingested, DMT and related N,N -dialkyltryptamines produce an intense hallucinogenic state. Behavioral effects are mediated through various neurochemical mechanisms including activity at sigma-1 and serotonin receptors, modification of monoamine uptake and release, and competition for metabolic enzymes. To further clarify the pharmacology of hallucinogenic tryptamines, we synthesized DMT, N -methyl- N -isopropyltryptamine (MIPT), N,N -dipropyltryptamine (DPT), and N,N -diisopropyltryptamine. We then tested the abilities of these N,N -dialkyltryptamines to inhibit [ 3 H]5-HT uptake via the plasma membrane serotonin transporter (SERT) in human platelets and via the vesicle monoamine transporter (VMAT2) in Sf9 cells expressing the rat VMAT2. The tryptamines were also tested as inhibitors of [ 3 H]paroxetine binding to the SERT and [ 3 H]dihydrotetrabenazine binding to VMAT2. Our results show that DMT, MIPT, DPT, and DIPT inhibit [ 3 H]5-HT transport at the SERT with K I values of 4.00 ± 0.70, 8.88 ± 4.7, 0.594 ± 0.12, and 2.32 ± 0.46 μM, respectively. At VMAT2, the tryptamines inhibited [ 3 H]5-HT transport with K I values of 93 ± 6.8, 20 ± 4.3, 19 ± 2.3, and 19 ± 3.1 μM, respectively. On the other hand, the tryptamines were very poor inhibitors of [ 3 H]paroxetine binding to SERT and of [ 3 H]dihydrotetrabenazine binding to VMAT2, resulting in high binding-to-uptake ratios. High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and also indicate that there are separate substrate and inhibitor binding sites within these transporters. The transporters may allow the accumulation of tryptamines within neurons to reach relatively high levels for sigma-1 receptor activation and to function as releasable transmitters.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>19756361</pmid><doi>10.1007/s00702-009-0308-8</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9564
ispartof Journal of Neural Transmission, 2009-12, Vol.116 (12), p.1591-1599
issn 0300-9564
1435-1463
language eng
recordid cdi_proquest_miscellaneous_21267762
source MEDLINE; Springer LINK 全文期刊数据库
subjects Animals
Basic Neurosciences
Blood Platelets - chemistry
Blood Platelets - drug effects
Blood Platelets - metabolism
Cell Line
Genetics and Immunology - Original Article
Hallucinogens - chemistry
Hallucinogens - metabolism
Hallucinogens - pharmacology
Humans
Medicine
Medicine & Public Health
N,N-Dimethyltryptamine - chemistry
N,N-Dimethyltryptamine - metabolism
N,N-Dimethyltryptamine - pharmacology
Neurology
Neurosciences
Paroxetine - chemistry
Paroxetine - metabolism
Paroxetine - pharmacology
Psychiatry
Rats
Serotonin - chemistry
Serotonin - metabolism
Serotonin Plasma Membrane Transport Proteins - chemistry
Serotonin Plasma Membrane Transport Proteins - metabolism
Serotonin Uptake Inhibitors - chemistry
Serotonin Uptake Inhibitors - metabolism
Serotonin Uptake Inhibitors - pharmacology
Spodoptera
Tetrabenazine - analogs & derivatives
Tetrabenazine - chemistry
Tetrabenazine - metabolism
Tetrabenazine - pharmacology
Tritium
Tryptamines - chemistry
Tryptamines - metabolism
Tryptamines - pharmacology
Vesicular Monoamine Transport Proteins - chemistry
Vesicular Monoamine Transport Proteins - metabolism
title Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dimethyltryptamine%20and%20other%20hallucinogenic%20tryptamines%20exhibit%20substrate%20behavior%20at%20the%20serotonin%20uptake%20transporter%20and%20the%20vesicle%20monoamine%20transporter&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=Cozzi,%20Nicholas%20V.&rft.date=2009-12-01&rft.volume=116&rft.issue=12&rft.spage=1591&rft.epage=1599&rft.pages=1591-1599&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTRF3&rft_id=info:doi/10.1007/s00702-009-0308-8&rft_dat=%3Cproquest_cross%3E733589521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217860167&rft_id=info:pmid/19756361&rfr_iscdi=true